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Histone variant macroH2A1 has two splice isoforms,
macroH2A1.1 and macroH2A1.2, with tissue- and cell-
specific expression patterns. Although macroH2A1.1 is
mainly found in differentiated, nonproliferative tissues,
macroH2A1.2 is more generally expressed, including in
tissues with ongoing cell proliferation. Consistently,
studies in breast and lung cancer have demonstrated a
strong correlation between macroH2A1.1 levels and
proliferation, which is not the case for macroH2A1.2.
This is the first study to assess the differential reg-
ulation and predictive potential of macroH2A1 iso-
forms in colon cancer. We found that macroH2A1.1
mRNA was down-regulated in primary colorectal
cancer samples compared to matched normal colon
tissue, whereas macroH2A1.2 was up-regulated. At
the protein level, down-regulation of macroH2A1.1
correlated significantly with patient outcome (P 
0.0012), and loss of macroH2A1.1 was associated
with a worse outcome. Over the course of Caco-2
cell differentiation, macroH2A1.1 was up-regulated
at both the RNA and protein levels, whereas
macroH2A1.2 was slightly down-regulated at the
RNA level and stable at the protein level. These
changes were accompanied by an antiproliferative
phenotype exhibiting features of cellular senes-
cence. Loss of macroH2A1.1 in vitro was character-
ized by a phenotype associated with cell growth and
metastasis. These data demonstrate that macroH2A1
isoforms are differentially regulated in colon can-
cer, reflecting the degree of cellular differentiation.
Notably, macroH2A1.1 expression predicts survival
in colon cancer, thus identifying macroH2A1.1 as a
novel colon cancer biomarker. (Am J Pathol 2012, 180:
2516–2526; http://dx.doi.org/10.1016/j.ajpath.2012.02.027)
Histone variants are nonallelic isoforms that replace con-
ventional histones within certain chromatin domains. By
2516altering the structure of the nucleosome, they contribute
select functions to chromatin. MacroH2A1 is a rather
special histone variant consisting of two domains, the
N-terminal histone fold and a C-terminal non-histone fold,
the macro domain.1 The macro domain, a 25-kDa-sized
globular module, distinguishes macroH2A from all known
core histones. Although the macro domain itself is con-
served among archaebacteria and viruses,2,3 histone
variant macroH2A appears to be restricted to verte-
brates, among which it is highly conserved.4 There are
two isoforms, macroH2A1.1 and macroH2A1.2, pro-
duced by alternative splicing of the H2AFY gene, which
differ in one single exon. Both isoforms have been asso-
ciated with states of silencing and transcriptional repres-
sion, such as facultative heterochromatin,5 centromeric
regions,6 and X inactivation,7 suggesting overlapping
functions for both splice variants. Yet, various studies
reveal isoform-specific properties. In vitro, the macro do-
main of macroH2A1.1, but not macroH2A1.2, binds ADP-
ribose and related NAD metabolites.3 Studies in mice
and rats show a differential expression pattern of
macroH2A1 isoforms in various tissues as well as during
development. Overall, macroH2A1.1 is mainly expressed
in differentiated, nonproliferative tissues, whereas the second
splice variant, macroH2A1.2, is more generally expressed,
including in tissues with ongoing cell proliferation.8,9
These findings are supported by studies in breast and
lung cancer, revealing a strong correlation between
macroH2A1.1 levels and proliferation, which has not been
found for macroH2A1.2. High levels of macroH2A1.1 are
associated with slowly proliferating lung cancers, whereas
highly proliferating tumors have markedly decreased
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been found to be similar in all tumors independently of
proliferation.10 Notably, expression of macroH2A1.1 has
been shown to be predictive of lung cancer recurrence,
identifying histone variant macroH2A1.1 as a novel bio-
marker in lung cancer.10
We now show that expression of macroH2A1.1 can
predict outcome in colon cancer, suggesting that
macroH2A1.1 could also serve as a useful prognostic
biomarker in colon cancer. We observed an increase of
macroH2A1.1 mRNA and protein over the course of dif-
ferentiation that is accompanied by an antiproliferative
phenotype exhibiting features of cellular senescence.
Loss of macroH2A1 in vitro is characterized by a pheno-
type favoring proliferation and metastasis.
Materials and Methods
Reverse Transcription and Quantitative
Real-Time PCR
RNA from 15 human colorectal cancer samples and 15
matched normal colon samples was acquired from Bio-
chain (Hayward, CA). RNA quality was assessed with the
Agilent Bio-Chip (Agilent, Santa Clara, CA) (RNA integrity
number 6.5). One microgram of RNA of each sample
was reverse-transcribed using the Superscript III First-
Strand Synthesis SuperMix and Oligo(dT)20 primers by
Invitrogen (Carlsbad, CA) according to the manufactur-
er’s instruction. Reverse transcription was followed by
RNase H digest (New England Biolabs, Ipswich, MA).
cDNA served as the quantitative PCR (qPCR) template.
To quantify the expression of the two macroH2A1 splice
variants, we performed SYBR Green quantitative real-
time PCR assays. Primer 311 and Primer Express soft-
ware V3.0 (Applied Biosystems, Foster City, CA) were
used to design exon-spanning qPCR primer pairs spe-
cific for macroH2A1.1 (5=-GCCTCTTCCTTGGCCA
GAA-3= and 5=-CACTGTCGATCGAGGCAATG-3=) and
macroH2A1.2 (5=-CTTTGAGGTGGAGGCCATAA-3= and
5=-TCTTCTCCAGCGTGTTTCCT-3=). qPCR reactions
were performed in triplicate using the Fast SYBR Green
Master Mix (Applied Biosystems) with a total reaction
volume of 20 L and primer concentrations of 100
nmol/L. The experiments were run on a 7900HT Fast
Real-Time PCR System (Applied Biosystems) following
the standard protocol for the Fast SYBR Green Master
Mix. A dissociation stage was added to the run protocol.
PCR efficiency was established by calibration curves us-
ing cDNA from Caco-2 cells as a template. Control reac-
tions were performed using genomic DNA as a template
and no template; both resulted in no amplification. Dis-
sociation curves were analyzed to ensure the specificity
of the detected signal. A common threshold was deter-
mined for both splice variant runs. Quantification cycle
values for each sample were transformed to relative
quantities, corrected for efficiency.
For normalization purposes, we quantified the expres-
sion of five reference genes: L19, GAPDH, B2M, RPLPO,
HPRT1. L19 was quantified in a SYBR Green assay ac-cording to the method described above, using the follow-
ing primers at a concentration of 100 nmol/L: (5=-AC-
CCCAATGAGACCAATGAAAT-3= and 5=-CAGCCCATC
TTTGATGAGCTT-3=). The other four reference genes
were quantified using Pre-Developed TaqMan Assay Re-
agents (4333764F, 4333766F, 4333761F, 4333768F; Ap-
plied Biosystems) and the TaqMan Gene Expression
Master Mix (Applied Biosystems). The experiments were
run on the same instrument following the standard proto-
col and conditions as outlined for the TaqMan Gene
Expression Master Mix. Quantification cycle values for
each sample were transformed to relative quantities, cor-
rected for efficiency, and the geometric mean of the five
reference genes was calculated for each sample. The
relative quantity of each sample determined in the splice
variant runs was normalized to the geometric mean of
the reference genes.12 The ratio of the normalized rela-
tive quantity of each cancer sample and its matched
normal colon sample was calculated and plotted on a
graph with a logarithmic scale, depicting the fold expres-
sion change in cancer versus normal tissue. In a second
graph, we plotted the normalized relative quantities for
each matched pair sample in a dot-and-line diagram and
performed a paired samples t-test using the MedCalc
software (version 11.4.4.0).
As a further quality control, we conducted a 3=:5=
assay to ensure the integrity of the RNA/cDNA and
used the Solaris qPCR control kit (Thermo Scientific,
Rockford, IL) to exclude any relevant inhibition of the
reactions.
Immunohistochemistry
A paraffin-embedded tissue multiarray containing 59
primary colorectal cancer samples was acquired from
Imgenex (San Diego, CA) and assessed for protein
expression of macroH2A1.1 and macroH2A1.2. Slides
were probed with isoform-specific rabbit polyclonal an-
tibodies against macroH2A1.1 (#4160; Cell Signaling
Technology, Danvers, MA) and macroH2A1.2 (YenZym
Antibodies, South San Francisco, CA). The antibody
against macroH2A1.2 was custom made and raised
against a peptide representing the alternatively spliced
exon specific for macroH2A1.2. Immunohistochemistry
was performed according to the standard protocol for
the Vectastain Universal Elite ABC kit (Vector Labora-
tories, Burlingame, CA), detected with diaminobenzi-
dine (Vector Laboratories), and counterstained with
Mayer’s hematoxylin (Sigma-Aldrich, St. Louis, MO).
Slides were scanned using the Aperio Scanscope XT
instrument at 20 (Aperio, Vista, CA). Tumor cells
within each core were selected for analysis using the
pen tool within the WebScope viewing software. The
Aperio Nuclear tool (Nuclear Analysis v9.1 algorithm,
see Supplemental Table S1 at http://ajp.amjpathol.org)
was used to analyze the nuclear staining intensity of
the cancer cells within each core. Fifty patient samples
with good-quality tissue in the cores were included in
the analysis (for patient characteristics, see Supple-
mental Table S2 at http://ajp.amjpathol.org). Three in-
tensity levels were discerned by the program: 3 (strong
2518 Sporn and Jung
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and 1 (weak or no staining). In addition, adjacent nor-
mal tissue found in the cores was analyzed accordingly
for the expression of macroH2A1.1 and macroH2A1.2.
To assess macroH2A1.1 expression levels in fetal
and adult tissue, we performed immunohistochemistry
against macroH2A1.1 on a slide containing adult human
heart tissue as well as heart tissue from a fetus at 16
weeks (Biochain). We did not perform staining against
macroH2A1.2, as striated muscle lacks expression of
macroH2A1.2.
Cell Culture Differentiation Experiment
Caco-2 cells, derived from human colorectal carci-
noma, were obtained from ATCC (Manassas, VA).
Caco-2 cells were tested for mycoplasma infection us-
ing the PCR Mycoplasma Detection Set (Takara, Otsu,
Japan) and authenticated by short tandem repeat pro-
filing using the PowerPlex 1.2 System (Promega, Fitch-
burg, WI). Caco-2 cells were grown in Iscove’s Modi-
fication of Dulbecco’s modified Eagle’s medium
(Mediatech, Manassas, VA) supplemented with 1%
(v/v) penicillin/streptomycin and 10% (v/v) heat-inacti-
vated fetal calf serum. For differentiation experiments,
cells were plated at passage 16 into 100-mm cell cul-
ture dishes (Corning, Corning, New York), at a density
of 5000 cells/cm2. Caco-2 cultures were allowed to
undergo proliferation and differentiation, and were har-
vested on days: 1, 3, 5, 7, 14, 21, and 28. For each day,
triplicate cell cultures were harvested. Cells were
washed with ice-cold PBS, collected by scraping, di-
vided into two tubes, and then centrifuged. One cell
pellet was flash-frozen in liquid nitrogen and stored at
80°C until further use; the second pellet was used for
immediate total RNA extraction using the RNeasy Plus
Mini Kit (Qiagen, Valencia, CA), including an on-col-
umn DNAseI digest as outlined by the manual. RNA
quality of the samples was determined by Agilent Bio-
Chip (RNA integrity number 9.5). Reverse transcrip-
tion and quantification by qPCR were performed as
described above.
Histone Extraction and Western Blot Analysis
After completion of the differentiation experiment, flash-
frozen samples were used for acid extraction of histones
using the EpiQuik Total Histone Extraction Kit (Epigentek,
Farmingdale, NY). Protein concentration was determined
by Quick Start Bradford Protein Assay with BSA as a
standard (BioRad, Hercules, CA). Three micrograms of
total histone per sample were loaded on a 4% to 20%
SDS gel (Expedeon, San Diego, CA), run under reducing
conditions and blotted on a polyvinylidene difluoride
membrane (Millipore, Billerica, MA). Blots were incu-
bated with the above-mentioned antibodies against
macroH2A1.1 and macroH2A1.2, followed by secondary
incubation with horseradish peroxidase–linked anti-rabbit
antibody (#7074; Cell Signaling) using the SNAP i.d. Pro-
tein Detection System (Millipore). Histone H3 was used
as a loading control (sc-10809; Santa Cruz Biotechnol-ogy, Santa Cruz, CA). Signal was detected with Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific) and visualized with the LAS-3000 (Fuji-
film USA, Valhalla, NY).
PCR Arrays
RT2 Profiler PCR Arrays were acquired from SABiosci-
ences (Frederick, MD) to analyze the expression of
genes associated with cell cycle regulation (PAHS-
020) and cellular senescence (PAHS-050). To compare
the expression of these genes in proliferating cells (low
macroH2A1.1 levels) with differentiated cells (high
macroH2A1.1 expression), we used Caco-2 RNA from
day 1 (low macroH2A1.1 expression) and day 21 (high
macroH2A1.1 expression) of the differentiation exper-
iment. RNA was reverse transcribed, and PCR arrays
were used in combination with the special formulated
and instrument-specific SYBR Green real-time PCR
master mixes (SABiosciences) according to the man-
ufacturer’s instructions. Data were analyzed using the
online PCR Array Data Analysis tool by SABiosciences.
Three biological replicates were used to determine the
mean expression in each group, and the geometric
mean over five housekeeping genes on each array was
used for normalization. The fold change of normalized
expression between proliferating and differentiated
Caco-2 cells was calculated by the analysis tool, and a
P value was determined. All genes that showed an
expression change greater than 1.5-fold along with P
values smaller than 0.05 were depicted on a graph with
a logarithmic scale.
All control features implemented on the array were
passed. No genomic DNA contamination was detected.
Reverse transcription controls indicated no inhibition of
the reaction. Positive PCR controls demonstrated inter-
well and intraplate consistency. Dissociation curves
showed specificity of the detected signal.
siRNA Knockdown of MacroH2A1.1 and
MacroH2A1.2
FET cells (a generous gift from Michael Brattain, Univer-
sity of Nebraska, Omaha, NE) were cultured in F12/Dul-
becco’s modified Eagle’s medium (Mediatech) supple-
mented with 10% (v/v) heat-inactivated fetal calf serum.
Cells were tested for mycoplasma infection and authen-
ticated as mentioned above. Specific small-interfering
RNAs (siRNAs) for macroH2A1.1 and macroH2A1.2 and
a non-targeting control siRNA (Ambion, Austin, TX) were
transiently delivered at a final concentration of 25 nmol/L
via electroporation using the AMAXA Nucleofector
(Lonza, Basel, Switzerland) in six-well plates at a density
of 2  106 cells per well. Transfection efficiency was
confirmed using the pmaxGFP Control Vector (Lonza).
Seventy-two hours post transfection, FET cells were
lysed for subsequent RNA and histone extraction as
described above. Knockdown was confirmed by quan-
titative real-time PCR and Western blot analysis ac-
cording to the methods above. RNA from three biolog-
ons are
formatio
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experiment was used for real-time PCR gene expres-
sion analysis using the PCR arrays by SABiosciences,
as described in detail earlier. All genes that showed an
expression change greater than 1.5-fold along with a
P value smaller than 0.05 (comparing knockdown ver-
sus control FET cells) were depicted on a graph with a
logarithmic scale.
Statistical Analysis
Survival data for the tissue multiarrays was provided by
Imgenex. The relationship between macroH2A1.1 and
macroH2A1.2 expression and overall survival was as-
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Results
MacroH2A1.1 Expression Is Down-Regulated in
Colon Cancer Compared to Matched Normal
Colon Tissue
MacroH2A1 is differentially regulated in distinct human
tissues and certain cancer types. Loss of macroH2A1
has been shown to predict an unfavorable prognosis in
lung cancer as well as in melanoma.10,13 To assess the
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(Figure 1), we used specific qPCR assays to quantify the
expression of macroH2A1.1 and macroH2A1.2 in human
colon cancer and matched normal colon tissue samples.
We found that although macroH2A1.1 levels were down-
regulated when comparing cancer with normal colon
samples (P  0.0035) (Figure 2A), macroH2A1.2 levels
were up-regulated (P  0.0112) (Figure 2B). This is con-
sistent with the idea of macroH2A1.1 as a marker of
cellular differentiation and suggests distinct functions for
both splice variants.
MacroH2A1.1 Expression Predicts Survival in
Colon Cancer
To assess the protein expression of macroH2A1.1 and
macroH2A1.2 in colon cancer samples, we performed
immunohistochemistry on colon cancer samples of 50
patients from a tissue microarray. Slides were
scanned, and the nuclear expression was determined
by the Aperio software (Figure 3A). To determine a
dependence of overall survival on expression of
macroH2A1.1 in colon cancer, we performed a log-
rank test in a univariate analysis. Interestingly, it re-
vealed a significant correlation between macroH2A1.1
expression and survival (P  0.0012). Patients with low
macroH2A1.1 expression had a worse outcome than
patients with high macroH2A1.1 levels (Figure 3B).
Contrarily, expression levels of macroH2A1.2 did not
show a significant correlation with survival (P 
0.1413) (see Supplemental Figure S1 at http://ajp.
amjpathol.org). This is in line with findings in lung can-
α-macroH2A1.
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with findings in melanoma, demonstrating an associa-
tion between the global loss of macroH2A variants and
an unfavorable prognosis,13 this suggests that gradual
loss of macroH2A1.1 might be a general feature in
carcinogenesis influencing the respective prognosis.
This not only identifies macroH2A1.1 as a novel tool of
risk stratification in colon cancer patients, but also
opens the prospect of a much wider use in cancer
diagnostics with a potentially broad prognostic value.
In accordance with our qPCR results, normal colon
mucosa demonstrated a strong nuclear macroH2A1.1
staining (Figure 3C).
MacroH2A1.1 Is Up-Regulated over the Course
of Differentiation
MacroH2A1.1 levels have been shown to correlate with
the proliferative index of cancer samples, and it has
been suggested that macroH2A1.1 levels reflect
the degree of cellular differentiation.10 Additionally,
macroH2A1.1 has been shown to be up-regulated dur-
ing cellular senescence, suggesting macroH2A1.1 as
a marker for cells that have exited the cell cycle.5,10 To
further investigate the role of macroH2A1 isoforms dur-
ing differentiation, we performed a cell culture experi-
ment that allowed us to observe macroH2A1 levels
over the course of differentiation. It has been shown
that Caco-2 cells become differentiated and polarized
when cultured beyond confluency under regular con-
ditions and that their phenotype resembles enterocytes
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are)of the small intestine.14 We harvested cells over the
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AJP June 2012, Vol. 180, No. 6course of 28 days, thus allowing us to compare cells in
the log phase of active proliferation, at confluency, and
after differentiation. Interestingly, we found an up-reg-
ulation of macroH2A1.1 transcript and protein over the
course of the experiment, reflecting the degree of cel-
lular differentiation (Figure 4, A and B). Notably, splice
isoform macroH2A1.2 behaved differently. Although tran-
script levels of macroH2A1.2 slightly decreased over the
course of differentiation, protein levels of macroH2A1.2
remained constant (Figure 4, A and B), which further
strengthened the idea of functionally distinct roles for
both splice variants. The dependence of macroH2A1.1
expression on the degree of differentiation was further
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Figure 4. Opposing regulation of macroH2A1 splice variants over the
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nuclear macroH2A1.1 staining, fetal heart tissue showed
only weak nuclear staining (Figure 4C). These results
paralleled findings in mice that showed strong staining of
both variants in adult kidney and liver, but decreased
macroH2A1.1 expression in the fetal counterpart.8
Changes in MacroH2A1.1 over the Course of
Differentiation Are Reflected by Changes in Cell
Cycle Regulation and Features of Cellular
Senescence
To further characterize the changes accompanying the
increase in macroH2A1.1 levels over the course of differ-
entiation, we performed pathway-focused qPCR analy-
ses using PCR arrays. PCR arrays are highly reliable tools
for the expression analysis of a focused panel of genes,
combining the profiling capability of microarrays with the
accuracy and reliability of validated quantitative real-time
PCR. We queried the transcript of 148 genes involved in
cell cycle regulation and cellular senescence, and com-
pared the expression levels of these genes in actively
proliferating (day 1) and differentiated (day 21) Caco-2
cells, characterized by low and high macroH2A1.1 levels,
respectively.
In differentiated cells, we found a global down-reg-
ulation of cell cycle markers crucial for cell cycle pro-
gression and proliferation involved in all phases of the
cell cycle (Figure 5A). We found a down-regulation of
genes associated with checkpoint and DNA damage
control, as well as a down-regulation of proliferation
markers resembling the state of cellular differentiation
and the lack of proliferation. A few genes were up-
regulated; among these were genes associated with
cell cycle arrest (CDKN1A, CDKN2B, RBL2) and
anti-proliferative or growth inhibitory action (CCNG1,
CCNG2).
MacroH2A1 isoforms have been shown to be up-
regulated during senescence, and macroH2A1.1 has
been described as an oncogene-induced senescence
marker in lung cancer development.10 Here, we show
that increase in macoH2A1.1 in Caco-2 cells coincided
with exhibition of senescent features (Figure 5B). The
decreased proliferative activity characteristic for se-
nescent cells was indicated by down-regulation of
genes expressing transcription factors (E2F1, ETS2,
TBX3), cyclins (CCNE1, CCNB1, CCNA2), and kinases
important for proliferation and growth (CDK6), as well
as genes controlling the cell cycle (CHEK1 and CHEK2,
CDK2ND). Genes expressing tumor suppressors and
associated proteins were up-regulated (RB1, RBL2,
PTEN), whereas oncogenes were down-regulated
(MYC, HRAS). We further found an up-regulation of
genes involved in cell cycle arrest and growth suppres-
sion (CDKN1A, CDKN1C, CDKN2B, CDKN2C, SPARC),
inducer of differentiation (IRF5, PRKCD), and enhancer
of senescence (CREG1). Genes responsible for devel-
opment of connective tissue (COL1A1, GLB1) were
also up-regulated. On the other hand, we observed a
striking down-regulation of the gene for telomerase
genes w
ging to
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AJP June 2012, Vol. 180, No. 6(TERT), which is an important characteristic of cellular
senescence. Inhibitor of differentiation (ID1) and pro-
proliferative genes were down-regulated (PCNA,
RBL1). Levels of collagen -1(III) (COL3A1), a collagen
type characteristic for fetal collagen and extracellular
matrix, were strongly decreased. Interestingly, we also
noted a down-regulation of genes found to be associ-
ated with migration and metastasis in other cancer
types (ALDH1A3, PLAU, FN1, CD44), as well as genes
with proangiogenic activity (THBS1), which resembles
the loss of tumorigenic potential observed in differen-
tiated Caco-2 cells.
Knockdown of MacroH2A1.1 Is Associated with
a Phenotype Favoring Tumor Growth and
Metastasis
To analyze the effects of loss of macroH2A1 isoforms,
we performed transient knockdowns of macroH2A1.1
and macroH2A1.2 in FET cells. The FET colon carci-
noma cell line is derived from an early stage human
colon cancer and as such possesses properties of
early malignant cells rather than advanced carcinoma
cells.15,16 FET cells are highly differentiated, but poorly
invasive17 cancer cells and show a fairly high base-
line expression of macroH2A1 isoforms. Different
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Figure 5. Changes of macroH2A1.1 are reflected by changes in cell cycle
expression between proliferating and differentiated Caco-2 cells was analyze
associated with cell cycle progression and proliferation, in conjunction w
macroH2A1.1 levels) exhibit features consistent with cellular senescence. All
than 0.05 were depicted on the graph with a logarithmic scale. Genes belonfrom Caco-2 cells, FET cells do not show varyingmacroH2A1 levels under regular culture conditions,
making them a suitable tool for assessing the effects of
macroH2A1 depletion in a cell line with a naturally high
and stable expression of macroH2A1. This approach
allowed us to assess the effects of varying macroH2A1
levels in a second independent cell-line model com-
plementing the Caco-2 differentiation experiment. RNA
from knockdown and control experiments was ana-
lyzed using the same PCR arrays as in the above
Caco-2 differentiation experiment (Figure 5). Expres-
sion changes were calculated comparing knockdown
to control cells. Overall, we observed more subtle ex-
pression changes than in the previous experiment. This
was expected, as we compared two sets of cancer
cells that were both proliferating, whereas previously,
we compared cells with two distinct phenotypes, colon
cancer cells on one hand and cells resembling entero-
cytes without tumorigenic potential on the other.
Knockdown of macroH2A1.1 was very specific and did
not lead to major changes in macroH2A1.2 levels, yet
knockdown of macroH2A1.2 involved a decrease in
macroH2A1.1 levels (Figure 6A).
FET cells with reduced macroH2A1.1 levels showed a
phenotype consistent with enhanced proliferation and DNA
replication (up-regulation of HERC5, BRCA2, CCND2,
HUS1, NBN, and CITED2), favoring survival (up-regulation
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AJP June 2012, Vol. 180, No. 6cent findings in chronic lymphocytic leukemia and small
lymphocytic lymphoma showing specific overexpression
of p15 (CDKN2B) along with up-regulation of CCND2 in
the proliferation centers of these tumors.18 Notably, we
observe an up-regulation of the gene for telomerase
(TERT), mirroring the results of the differentiation experi-
ment, as well as other genes with known oncogenic po-
tential (BMI1, EGR1, ETS1, HERC5). Especially interesting
is the up-regulation of several genes that have been
shown to be involved in migration and metastasis in var-
ious other cancer types (ALDH1A3, CDK5R1, FN1, PLAU,
SERPINE1, SPARC) (see Supplemental Table S318–43 at
http://ajp.amjpathol.org).
Results of the macroH2A1.2 knockdown revealed a
similar phenotype (Figure 6C). Yet, seven genes that
were changed after knockdown of macroH2A1.1 were
not changed after macroH2A1.2 knockdown (CDK5R1,
HUS1, CCND2, BMI1, PLAU, NBN, FN1). Two additional
genes were found to be changed (CCND1, IGF1R). Al-
though the effects of the macroH2A1.1 knockdown can
be considered specific, it is unclear whether and to what
degree the results of the macroH2A1.2 knockdown are
influenced by the decrease of macroH2A1.1 (Figure 6A).
Thus, the similar phenotype observed could be explained
either by a functional overlap of both splice variants in FET
cells or by the concomitant decrease in macroH2A1.1 ob-
served following macroH2A1.2 knockdown. In summary,
we can only conclude that loss of macroH2A1.1 leads to a
phenotype associated with enhanced migration, prolifera-
tion, and cell survival.
Discussion
Histones are often assumed to be expressed at similar
levels in different cell types. Yet, this is not the case for
macroH2A1. MacroH2A1 is unusual in several molec-
ular and cellular features. At the structural level, it
carries a huge globular domain, the macro domain.
Further, there are two splice variants, macroH2A1.1
and macroH2A1.2, that differ in only one exon. Despite
a certain overlap that has been described for the dis-
tribution and function of these isoforms, several studies
point to explicit differences between macroH2A1.1 and
macroH2A1.2, supporting the idea of functionally dis-
tinct isoforms.
Here, we show that whereas macroH2A1.1 is de-
creased in colon cancer versus matched normal colon
samples at the RNA level, macroH2A1.2 expression is
increased, which supports the concept of functional dif-
ferences. Consistently, we find strong macroH2A1.1 pro-
tein expression in normal colon mucosa and varying ex-
pression in different colon cancer samples. Notably, only
expression of macroH2A1.1 predicts outcome in colon
cancer. Patients with low levels of macroH2A1.1 have a
worse outcome than patients with high levels. This iden-
tifies macroH2A1.1 as a novel tool of risk stratification in
colon cancer patients and establishes macroH2A1.1 as a
predictive biomarker in another cancer type. Together
with previous findings that characterized macroH2A1.1
as a predictor of lung cancer recurrence and showed anassociation of global loss of macroH2A variants and mel-
anoma progression,10,13 this suggests that loss of
macroH2A1.1 might be a general feature of carcinogen-
esis that is linked to the aggressiveness of the tumor and,
thus, to the prognosis of the patient. Utilization of
macroH2A1.1 as a prognostic marker might have a broad
clinical application that should be addressed in future
studies in more cancer types.
We further show that macroH2A1.1 increases with
differentiation in vitro. These changes are reflected by
changes of cell cycle regulation and features of cellular
senescence that we characterized by pathway-fo-
cused qPCR arrays assessing 148 genes. Quantitative
PCR arrays are powerful tools to determine expression
changes, combining the advantage of multiple gene
profiling of arrays with the sensitivity and specificity of
quantification by validated real-time PCR, thus provid-
ing very reliable and reproducible data. Using this
approach, we found a phenotype that is enriched for
macroH2A1.1 and marked by down-regulation of
genes associated with cell cycle progression and pro-
liferation, in conjunction with up-regulation of growth
inhibitory genes and genes characteristic for senes-
cent cells. This correlates with previous results that
demonstrated an enrichment of macroH2A1.1 in lung
adenomas, a model of oncogene-induced senes-
cence, along with loss of macroH2A1.1 in lung adeno-
carcinoma cells that had overcome senescence.10 We
conclude that macroH2A1.1 might be a general marker
of cellular senescence, reflecting the degree of cellular
differentiation.
Additionally, we find that loss of macroH2A1.1 is char-
acterized by a pro-proliferative phenotype favoring cell
survival, as well as migration and metastasis. Remark-
ably, macroH2A1.1 knockdown is associated with up-
regulation of a variety of genes that have been demon-
strated to play important roles in carcinogenesis and to
possess prognostic potential with respect to stage,
grade, metastasis, and survival in various cancer types.
These data explain and strongly support the prognostic
correlation between macroH2A1.1 levels and outcome
that we demonstrated in vivo.
Colon cancer derives from an imbalance in prolifer-
ation, differentiation, and apoptosis of epithelial cells.
Once proliferation predominates, benign tumors,
called adenomas, emerge that are known to be en-
riched in senescent cells.44 Eventually, these adeno-
mas may evolve into cancer, and in an advanced
stage, cancer cells may invade surrounding tissues
and metastasize. Here, we show that macroHA1.1 is
involved in the regulation of proliferation, differentia-
tion, senescence, and migration in colon cancer, sug-
gesting an important role in colorectal carcinogenesis
and possibly in carcinogenesis in general. We demon-
strate that macroH2A1.1 predicts survival in colon can-
cer patients, providing a novel prognostic tool for strat-
ification of colon cancer patients. This is another step
toward clinical utilization of markers that help to define
individual risk signatures in patients, leading to better
targeting of therapeutic strategies and ultimately im-
proving the overall survival in cancer patients.
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